TSRL, Inc. to Present at the 2015 AAPS Annual Meeting and Exposition
/Ann Arbor, Michigan, Sept 15th, 2015: TSRL Inc., a preclinical accelerator developing novel anti-infective therapeutics in areas of high unmet medical need, is presenting at the 2015 AAPS Annual Meeting and Exposition, October 25-29, at the Orange County Convention Center in Orlando Florida.
Dawn Reyna, Sr. Director of Laboratory Services, will be presenting on the "Pharmacokinetics of Potent HPMPA and HPMPC Tyrosinamide Prodrugs with Broad Spectrum Antiviral Activity" and Deanna Mudie, on behalf of the University of Michigan College of Pharmacy, will be presenting on the "Influence of Fluid Shear Rate on the Dissolution Rate of Poorly Soluble Drug Particles; Implications for In Vivo Predictive In Vitro Dissolution Methodologies and Mechanistic Computational Modeling".
Abstracts are available here:
Influence of Fluid Shear Rate on the Dissolution Rate of Poorly Soluble Drug Particles
About TSRL, Inc.
TSRL, Inc. is a privately-held anti-infectives drug development firm and accelerator focused on R&D efforts to optimize effectiveness and safety of investigational and marketed therapeutics. More information about TSRL, Inc. is available on the company website www.tsrlinc.com or can be requested by contacting Dr. Elke Lipka, President, 734-663-4233 x236, elipka@tsrlinc.com.
